Logo image of HSCS

HEARTSCIENCES INC (HSCS) Stock Fundamental Analysis

USA - NASDAQ:HSCS - US42254E3027 - Common Stock

3.405 USD
-0.1 (-2.99%)
Last: 10/16/2025, 8:00:02 PM
Fundamental Rating

2

HSCS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. HSCS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HSCS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HSCS has reported negative net income.
In the past year HSCS has reported a negative cash flow from operations.
In the past 5 years HSCS always reported negative net income.
HSCS had a negative operating cash flow in each of the past 5 years.
HSCS Yearly Net Income VS EBIT VS OCF VS FCFHSCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

HSCS has a worse Return On Assets (-136.22%) than 83.77% of its industry peers.
With a Return On Equity value of -279.15%, HSCS is not doing good in the industry: 75.92% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -136.22%
ROE -279.15%
ROIC N/A
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HSCS Yearly ROA, ROE, ROICHSCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

The Gross Margin of HSCS (57.14%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of HSCS has grown nicely.
HSCS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
HSCS Yearly Profit, Operating, Gross MarginsHSCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K

More info and screens

5

2. Health

2.1 Basic Checks

HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HSCS has been increased compared to 1 year ago.
The number of shares outstanding for HSCS has been reduced compared to 5 years ago.
The debt/assets ratio for HSCS is higher compared to a year ago.
HSCS Yearly Shares OutstandingHSCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
HSCS Yearly Total Debt VS Total AssetsHSCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -19.28, we must say that HSCS is in the distress zone and has some risk of bankruptcy.
HSCS has a worse Altman-Z score (-19.28) than 89.53% of its industry peers.
There is no outstanding debt for HSCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.28
ROIC/WACCN/A
WACC8%
HSCS Yearly LT Debt VS Equity VS FCFHSCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

A Current Ratio of 1.47 indicates that HSCS should not have too much problems paying its short term obligations.
The Current ratio of HSCS (1.47) is worse than 76.44% of its industry peers.
HSCS has a Quick Ratio of 1.25. This is a normal value and indicates that HSCS is financially healthy and should not expect problems in meeting its short term obligations.
HSCS's Quick ratio of 1.25 is on the low side compared to the rest of the industry. HSCS is outperformed by 67.54% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.25
HSCS Yearly Current Assets VS Current LiabilitesHSCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

HSCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.48%, which is quite impressive.
HSCS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -76.34%.
The Revenue for HSCS have been decreasing by -41.50% on average. This is quite bad
EPS 1Y (TTM)79.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.15%
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A

3.2 Future

HSCS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.73% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.91%
EPS Next 2Y22.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HSCS Yearly Revenue VS EstimatesHSCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2027 500K 1M 1.5M
HSCS Yearly EPS VS EstimatesHSCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HSCS. In the last year negative earnings were reported.
Also next year HSCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSCS Price Earnings VS Forward Price EarningsHSCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSCS Per share dataHSCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as HSCS's earnings are expected to grow with 22.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.73%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

HSCS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEARTSCIENCES INC

NASDAQ:HSCS (10/16/2025, 8:00:02 PM)

3.405

-0.1 (-2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-11 2025-09-11/amc
Earnings (Next)N/A N/A
Inst Owners2.33%
Inst Owner Change0%
Ins Owners1.67%
Ins Owner Change-16.78%
Market Cap9.02M
Analysts82.5
Price Target13.77 (304.41%)
Short Float %4.27%
Short Ratio0.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.28%
Min EPS beat(2)18.08%
Max EPS beat(2)18.47%
EPS beat(4)3
Avg EPS beat(4)9.66%
Min EPS beat(4)-6.31%
Max EPS beat(4)18.47%
EPS beat(8)4
Avg EPS beat(8)-46.62%
EPS beat(12)7
Avg EPS beat(12)-29.34%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.85%
EPS NQ rev (1m)-7.92%
EPS NQ rev (3m)-3.95%
EPS NY rev (1m)16.36%
EPS NY rev (3m)14.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1432.26
P/FCF N/A
P/OCF N/A
P/B 2.87
P/tB 5.92
EV/EBITDA N/A
EPS(TTM)-8.3
EYN/A
EPS(NY)-4.62
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.77
OCFYN/A
SpS0
BVpS1.19
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -136.22%
ROE -279.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.14%
FCFM N/A
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 92.07%
Cap/Sales 479.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.25
Altman-Z -19.28
F-Score2
WACC8%
ROIC/WACCN/A
Cap/Depr(3y)199.15%
Cap/Depr(5y)121.34%
Cap/Sales(3y)570.65%
Cap/Sales(5y)345.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.15%
EPS Next Y30.91%
EPS Next 2Y22.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.93%
OCF growth 3YN/A
OCF growth 5YN/A